Plain-English translation of NCT04159142 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether nab-paclitaxel works better when combined with carboplatin or with capecitabine for treating advanced triple-negative breast cancer — a more aggressive form of breast cancer that lacks three common markers that other breast cancers have. About 414 women will participate across multiple hospitals to compare how well these two medication combinations work and what side effects they cause.
Triple-negative breast cancer is more aggressive and harder to treat than other breast cancers because standard hormone-based therapies don't work for it. This trial exists to find the best chemotherapy combination to help women with this diagnosis live longer and better.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous chemotherapy infusions on a set schedule over 21-day cycles for 6 cycles (about 4–5 months). After completing the initial chemotherapy, you would continue taking one of the medications by mouth to help keep the cancer controlled for as long as it's working. You'll have regular blood tests and scans to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China